Liraglutide Injection
NDC 70377-094
Product Information
Liraglutide is a ANDA-approved product labeled by Biocon Pharma Inc.. This medication is used with a doctor-approved exercise, behavior change, and reduced-calorie diet program to help you lose weight. It is supplied as a injection for subcutaneous administration. This product entry covers the primary NDC 70377-094 and 2 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 70377-094?
What are the uses of this product?
What are Active Ingredients of this product?
- LIRAGLUTIDE 6 mg/mL - An analog of GLUCAGON-LIKE PEPTIDE 1 and agonist of the GLUCAGON-LIKE PEPTIDE 1 RECEPTOR that is used as a HYPOGLYCEMIC AGENT and supplemental therapy in the treatment of DIABETES MELLITUS by patients who do not respond to METFORMIN.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- LIRAGLUTIDE (UNII: 839I73S42A)
- LIRAGLUTIDE (UNII: 839I73S42A) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- PHENOL (UNII: 339NCG44TV)
- PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
- WATER (UNII: 059QF0KO0R)
- TRISODIUM CITRATE DIHYDRATE (UNII: B22547B95K)
- HYDROCHLORIC ACID (UNII: QTT17582CB)
- SODIUM HYDROXIDE (UNII: 55X04QC32I)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 897122 - liraglutide 6 MG/ML in 3 ML Pen Injector
- RxCUI: 897122 - 3 ML liraglutide 6 MG/ML Pen Injector
- RxCUI: 897122 - liraglutide 18 MG per 3 ML Pen Injector
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.